Johnson & Johnson JNJ

$280.78 -1.33 (-0.47%)

Valuation

Market cap
679,126,272,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.94
P/E (forward)
24.85
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,385,600
Avg volume
7,225,794
Day's range
$279.19 – $283.25
Shares out
2,407,310,000
Stochastic %K
86%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

UnMaker Nov 11, 2:40 PM
$BB Investors are shifting into this gem from all our partnerships $GOOG $AMZN $AMD $JNJ The derisking and search for value opportunities is growing and this is poised for huge growth.
0 replies
HydrogenH2 Nov 11, 2:36 PM
$JNJ Elliott ... lol ?
0 replies
ElliottwaveForecast Nov 11, 1:01 PM
📈 $JNJ continues to maintain a strong bullish Elliott Wave structure and remains on track to extend higher within its daily uptrend from the May 2026 low. 🚀 The current rally is expected to continue towards the 271.37 target and potentially beyond as wave ((5)) unfolds. Any short-term pullback against the 06.22.2026 low should remain supported, providing opportunities for the next leg higher within the ongoing bullish sequence. 👉 Read the full analysis: https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #JNJ #ElliottWave #Trading #Investing #TechnicalAnalysis #StockMarket #Healthcare #PriceAction #MarketOutlook #SwingTrading
1 replies
HydrogenH2 Nov 11, 12:19 PM
$JNJ $ABBV $UNH $LLY Morningstar now ranks healthcare as the third most overvalued US sector after its rally. Earnings also remain a test. Johnson & Johnson's October results disappointed and handed the sector its weakest stretch in over a month, Bloomberg reported.
0 replies
TalkMarkets Nov 11, 5:33 AM
Q3 Earnings Season Winners: 3 Companies Raising Guidance $BWXT $JNJ $UNH https://talkmarkets.com/article/q3-earnings-season-winners-3-companies-raising-guidance
0 replies
Techdamentals Nov 11, 1:50 AM
The Dow fell 0.30% on Tuesday, November 10, 2026, less than the Nasdaq's 0.74% drop, after hotter-than-expected October CPI, the government's monthly measure of inflation. One number from $JNJ's latest report: worldwide sales rose 5.9% to $25.399 billion in the third quarter of 2026, from $23.993 billion a year earlier. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/JNJ?ref=st
0 replies
Biotechsamy Nov 10, 10:36 PM
$LEGN if In Vivo CAR-T clinical data was not promising, Frank at LEGN would have sold the company to $JNJ earlier this year at the best price possible that he could negotiate, before it’s get ugly with Anito cel approval. But he didn’t budge probably for a reason. Let’s hope for the best outcome, but not everyone can practice patience.
1 replies
JFais Nov 10, 10:21 PM
Key ?'s for $JNJ's bleximenib ASH abstract: -1/3rd of patients missing from their efficacy analysis (ITT 146, 100 EEP) Were there deaths or patients coming off drug early? Grade 3+ cytopenias 35%, also seeing DS, QTc & myelosuppression (could have problems with combinations) (more notes on the menin space in Chat)
0 replies